The Spero Project, a local resettlement agency, will host a walk at Scissortail Park to raise money to help refugees in t ...

In the last week, the market has been flat, but over the past 12 months, it has risen by 12%, with earnings forecast to grow by 14% annually. While traditional investments often focus on established ...

Spero Therapeutics, Inc. (NASDAQ:SPRO) saw its stock surge by 240% on May 28 following the company’s announcement of the ...

These 10 Firms Crushed The Market Last Week. In this article, we are going to take a look at where Spero Therapeutics, ...

Both companies viewed the early end to the PIVOT-PO trial as a positive development, with GSK saying it would work with US ...

Spero Therapeutics Inc. (NASDAQ: SPRO) stock has reached a notable milestone, hitting a 52-week high of $2.53 USD. This peak reflects a significant turnaround for the biopharmaceutical company ...

Thanks to American Unagi, the first land-based, large-scale eel aquafarm in the United States, eel no longer has to cross ...

Spero Therapeutics (SPRO) stock rocketed on Wednesday after the clinical-stage biopharmaceutical company revealed results from a study conducted with GlaxoSmithKline (GSK). These results come from its ...

Spero Therapeutics, Inc. (NASDAQ:SPRO) saw its stock surge by 240% on May 28 following the company’s announcement of the successful completion of the pivotal Phase 3 PIVOT-PO trial for ...

Spero Therapeutics (Nasdaq: SPRO) is making headlines as its stock experienced a remarkable 244% surge to $2.35 yesterday, on news of positive clinical trial results.

GSK & Spero Therapeutics announce PIVOT-PO phase III study for tebipenem HBr stopped early for efficacy following review by IDMC: London, UK Friday, May 30, 2025, 15:00 Hrs [IST] ...

Major health sector news includes GSK and Spero stopping a UTI drug trial due to early success, Brazil's bird flu cases and ...